C
Chee-Seng Yee
Researcher at Doncaster Royal Infirmary
Publications - 32
Citations - 783
Chee-Seng Yee is an academic researcher from Doncaster Royal Infirmary. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 23 publications receiving 644 citations. Previous affiliations of Chee-Seng Yee include Birmingham City Hospital & University of Birmingham.
Papers
More filters
Journal ArticleDOI
Prevalence and predictors of fragility fractures in systemic lupus erythematosus
TL;DR: Reduced BMD, osteoporosis, and fragility fractures appear to be prevalent in patients with SLE, and Steroids were not an independent risk factor for fractures, although their effect could be mediated through reduced bone mineral density.
Journal ArticleDOI
Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus
TL;DR: Although autoantibodies are useful in diagnosis and predicting disease activity in SLE, they do not appear to be useful in predicting damage in Sle.
Journal ArticleDOI
Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years
Chee-Seng Yee,Li Su,Veronica Toescu,Richard A. Hickman,Deva Situnayake,Simon J Bowman,Vernon Farewell,Caroline Gordon +7 more
TL;DR: SLE patients have premature mortality, and the predictors for damage accrual were higher prior damage, older age at diagnosis, active disease, systemic corticosteroid exposure and CYC exposure, which were independently associated with the development of damage.
Journal ArticleDOI
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis
Chee-Seng Yee,Caroline Gordon,C. Dostal,P Petera,J. Dadoniene,Bridget Griffiths,Blaž Rozman,David A. Isenberg,Gunnar Sturfelt,Ola Nived,JH Turney,Algirdas Venalis,Dwomoa Adu,Josef S. Smolen,Paul Emery +14 more
TL;DR: There was no statistically significant difference in efficacy and side effects between the two regimens, and Infectious complications occurred commonly, so careful monitoring is required during treatment.
Journal ArticleDOI
Effects of rituximab on resistant SLE disease including lung involvement.
John A. Reynolds,V. Toescu,Chee-Seng Yee,Athiveeraramapandian Prabu,D Situnayake,Caroline Gordon +5 more
TL;DR: Rituximab was beneficial in refractory systemic lupus erythematosus including severe neurological and cardiorespiratory disease by inducing disease remission, allowing withdrawal of other agents and reduction in steroid requirement.